Eli Lilly (LLY) came out with quarterly earnings of $3.34 per share, missing the Zacks Consensus Estimate of $3.52 per share. This compares to earnings of $2.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.11%. A quarter ago, it was expected that this drugmaker would post earnings of $5.03 per share when it actually produced earnings of $5.32, delivering a surprise of 5.77%.Over the last four quarters, the company has su ...

Teleflex (TFX) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.88 per share. This compares to earnings of $3.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.04%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.86 per share when it actually produced earnings of $3.89, delivering a surprise of 0.78%.Over the last four quarters, the co ...

Smurfit Westrock (SW) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.31%. A quarter ago, it was expected that this paper and packaging company would post earnings of $0.68 per share when it actually produced earnings of $0.34, delivering a surprise of -50%.Over the last four quart ...

CVS Health (CVS) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 31.58%. A quarter ago, it was expected that this drugstore chain and pharmacy benefits manager would post earnings of $0.89 per share when it actually produced earnings of $1.19, delivering a surprise of 33.71%.Over the ...

Core Viewpoint - Markel Group reported quarterly earnings of $25.72 per share, exceeding the Zacks Consensus Estimate of $18.89 per share, and showing an increase from $18.17 per share a year ago, representing an earnings surprise of 36.16% [1] Financial Performance - The company posted revenues of $3.55 billion for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.01%, and down from $3.56 billion year-over-year [2] - Over the last four quarters, Markel Group has surpassed consensus EPS estimates three times, but has not beaten consensus revenue estimates during the same period [2] Stock Performance - Markel Group shares have increased approximately 5.4% since the beginning of the year, contrasting with the S&P 500's decline of 5.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $24.33 on revenues of $4 billion, and for the current fiscal year, it is $92.82 on revenues of $15.3 billion [7] - The trend of estimate revisions for Markel Group is mixed, which may change following the recent earnings report [6] Industry Context - The Diversified Operations industry, to which Markel Group belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - Udemy, Inc. reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of $0.10 per share, and showing an increase from $0.03 per share a year ago, representing an earnings surprise of 20% [1] - The company posted revenues of $200.3 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.66%, and an increase from $196.85 million year-over-year [2] - Over the last four quarters, Udemy has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Future Outlook - The sustainability of Udemy's stock price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $195.94 million, and for the current fiscal year, it is $0.41 on revenues of $791.3 million [7] - The estimate revisions trend for Udemy is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Internet - Software industry, to which Udemy belongs, is currently ranked in the bottom 44% of over 250 Zacks industries, suggesting that the industry's outlook can significantly impact Udemy's stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Wyndham Hotels (WH) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.88%. A quarter ago, it was expected that this hotel and resort chain would post earnings of $1 per share when it actually produced earnings of $1.04, delivering a surprise of 4%.Over the last four quarters, the comp ...

Company Performance - Tandem Diabetes Care, Inc. reported a quarterly loss of $0.67 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.60, and compared to a loss of $0.63 per share a year ago, indicating an earnings surprise of -11.67% [1] - The company posted revenues of $234.42 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.44%, and showing an increase from year-ago revenues of $191.67 million [2] - Over the last four quarters, Tandem Diabetes Care has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Tandem Diabetes Care shares have declined approximately 53.4% since the beginning of the year, in contrast to the S&P 500's decline of -5.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $247.82 million, and for the current fiscal year, it is -$1.17 on revenues of $1 billion [7] Industry Outlook - The Medical - Instruments industry, to which Tandem Diabetes Care belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The performance of Tandem Diabetes Care's stock may be influenced by the overall outlook for the industry [8]

OPKO Health (OPK) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -66.67%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.11 per share when it actually produced earnings of $0.01, delivering a surpr ...

Core Viewpoint - CareDx reported quarterly earnings of $0.09 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and showing improvement from a loss of $0.03 per share a year ago, indicating a 50% earnings surprise [1] - The company posted revenues of $84.69 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.30%, but showing growth from $72.05 million year-over-year [2] Financial Performance - CareDx has surpassed consensus EPS estimates in all four of the last quarters, with a notable earnings surprise of 157.14% in the previous quarter [2][1] - The current consensus EPS estimate for the upcoming quarter is $0.13, with expected revenues of $90.31 million, and for the current fiscal year, the EPS estimate is $0.58 on revenues of $370.95 million [7] Market Position - CareDx shares have underperformed the market, losing approximately 15.3% since the beginning of the year, compared to a decline of 5.5% in the S&P 500 [3] - The Zacks Rank for CareDx is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Industry Outlook - The Medical Services industry, to which CareDx belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]